The US Patent and Trademark Office has granted Exalenz Bioscience the first patent for its BreathID Platform technology's method of evaluating the liver condition of a patient.
By computing and comparing breath test parameters, before and after ingestion of a test substrate, while collecting a continuous flow of the patient's breath, Exalenz's breath test liver application will assess the liver condition of a patient.
Exalenz CEO Lawrence Cohen said the company intends to develop a product pipeline based on the BreathID Technology Platform.
"It has been a busy summer. In July, we launched the BreathID Hp for the detection and management of the H. pylori bacteria," Cohen added.
"We also established a new direct US sales team purposed to better service our valued customers. We are looking forward to continuing the momentum and to more exciting developments in the fall."
Exalenz develops advanced diagnostic systems that use the continuous flow of a patient's breath to diagnose and help manage digestive system and liver conditions.